High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model

Yonsei Medical Journal

Volumn 48, Issue 4, 2007, Pages 653-658

  Yang, Kyu Hyun ^a   Won, Jung Hoon ^a   Yoon, Han Kook ^a   Ryu, Jong Hyeon ^b   Choo, Kyo Seok ^b   Kim, Jae Shin ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Central Research Institute   (South Korea)

Author keywords

Fracture healing; Mechanical strength; Pamidronate

Indexed keywords

PAMIDRONIC ACID;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE NECROSIS; BONE STRENGTH; BONE STRESS; CALLUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG BONE LEVEL; FEMALE; FEMUR; FEMUR FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOAD CARRYING CAPACITY; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; RIGIDITY; TREATMENT DURATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; FRACTURE HEALING; OSTEOPOROSIS; RATS; RATS, SPRAGUE-DAWLEY; STRESS, MECHANICAL;

EID: 34848914849     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.4.653     Document Type: Article

References (22)

1. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten year's experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
2. Fleisch H. Bisphosphonates in bone disease. 4th ed. San Diego: Academic Press; 2000.
3. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
4. Ott SM, Long-term safety of biophosphonates. J Clin Endocrinol Metab 2005;90:1897-9.
5. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353: 99-102.
6. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63: 1567-75.
7. Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003;18:512-20.
8. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63.
9. Bonnarens F, Einhorn TA. Production of a standard dosed fracture in laboratory animal bone. J Orthop Res 1984;2:97-101.
10. Hoggarth CR, Bennett R, Daley-Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int 1991; 49:416-20.
11. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993;14:595-608.
12. King LE, Vieth R. Extraction and measurement of pamidronate from bone samples using automated precolumn derivatization, high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl 1996;678:325-30.
13. Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002;17:2237-46.
14. Goodship AE, Walker PC, Mc Nally D, Chambers T, Green JR. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 1994;5 Suppl 7:S53-5.
15. Koivukangas A, Tuukkanen J, Kippo K, Jämsä T, Hannuniemi R, Pasanen I, et al. Long-term administration of clodronate does not prevent fracture healing in rats. Clin Orthop Relat Res 2003;408:268-78.
16. Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H. Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 1999;14: 969-79.
17. Yang KH, Park SY, Yoo JH, Kim TH, Park HW, Ryu JH, et al. Effect of the long-term administration of pamidronate on bone strength and fracture healing in a rat model. J Korean Orthop Assoc 2005;40:1043-9.
18. Lehman RA, Kuklo TR, Freedman BA, Cowart JR, Mense MG, Riew KD. The effect of alendronate sodium on spinal fusion: a rabbit model. Spine J 2004;4:36-43.
19. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
20. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19:1779-86.
21. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-4.
22. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993;342:1459-60.